Apetinil — Competitive Intelligence Brief

Apetinil (ETILAMFETAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: etilamfetamine. Area: Pain.

phase 2 etilamfetamine Sigma non-opioid intracellular receptor 1 Pain Small molecule

Target snapshot

Apetinil (ETILAMFETAMINE). Apetinil works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various physiological processes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apetinil TARGET	ETILAMFETAMINE		phase 2	etilamfetamine	Sigma non-opioid intracellular receptor 1
Aricept	DONEPEZIL	Eisai	marketed	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
Naftin	NAFTIFINE	Legacy Pharma	marketed	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	marketed	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Gocovri	AMANTADINE	Endo	marketed	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Aralen	CHLOROQUINE	Sanofi	marketed	Antimalarial	Sigma non-opioid intracellular receptor 1	1949-01-01
Pentoxiverine	pentoxyverine		marketed	Central Nervous System Stimulant [EPC]	Sigma non-opioid intracellular receptor 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (etilamfetamine class)

1. · 1 drug in this class